

| Market Applicability |    |    |    |    |    |    |    |
|----------------------|----|----|----|----|----|----|----|
| Market               | DC | GA | KY | MD | NJ | NY | WA |
| Applicable           | X  | X  | X  | X  | X  | X  | NA |

## Adakveo (crizanlizumab)

| Override(s)         | Approval Duration |
|---------------------|-------------------|
| Prior Authorization | 1 year            |

| Medications                             | Dosing Limit           |
|---|------------------------|
| Adakveo (crizanlizumab) 10 mg/ ml vial* | 5 mg/ kg every 4 weeks |

\*Initiation of therapy for Adakveo: May approve 5mg/kg at week 0 and week 2.

### APPROVAL CRITERIA

Requests for Adakveo (crizanlizumab) may be approved if the following criteria are met:

- I. Individual is 16 years of age or older; **AND**
- II. Individual has a diagnosis of sickle cell disease; **AND**
- III. Prior to initiation of Adakveo therapy, individual had at least two episodes of sickle cell related pain crises in the past 12 months.

### Key References:

1. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. *N Engl J Med.* 2017;376(5):429-439.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: September 10, 2019.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

PAGE 1 of 2 02/24/2020  
New Program Date 02/24/2020

CRX-ALL-0520-20

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

| Market Applicability |    |    |    |    |    |    |    |
|----------------------|----|----|----|----|----|----|----|
| Market               | DC | GA | KY | MD | NJ | NY | WA |
| Applicable           | X  | X  | X  | X  | X  | X  | NA |

5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
6. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on September 10, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.